Abstract 2640: HBI-2375, a first-in-class IND ready selective MLL1-WDR5 inhibitor, retains desirable preclinical characteristics | AcademicGPT, tlooto

HBI-2375 represents a first-in-class MLL1-WDR5 inhibitor with promising characteristics for future testing in the clinic and retains desirable preclinical characteristics in solid tumors and in leukem (2024), CANCER RESEARCH, Shojaei F. | AcademicGPT, tlooto for Academic and Research